Global HIV/AIDS Diagnostics Market 2017-2022 – HIV/HIV-1/2/Combo, HIVAg/ NAT, Western Blot, HTLV-I/II –

HIV/AIDS Diagnostics Market 2017-2022”
report has been added to’s

Global HIV/AIDS Diagnostics Market 2017-2022: Supplier Country Shares,
Segment Volume and Sales Forecasts for Immunodiagnostic and NAT
Procedures – HIV 1/2, Combo, Ag, NAT, Western Blot – Blood Banks,
Commercial Labs, Hospitals, Physician Offices, Public Health Labs

This 7-country report presents detailed analyses of the AIDS diagnostics
market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.

For each country, the report provides test volume and sales forecasts
for HIV/HIV-1/2/Combo, HIVAg/ NAT, Western Blot, HTLV-I/II and other
confirmatory tests performed in the following market segments:

  • Hospitals
  • Commercial/Private Laboratories
  • Blood Banks
  • Physician Offices
  • Public Health Laboratories

For each country, in addition to test volume and sales projections, the
report presents sales and market share estimates for major suppliers of
AIDS tests.


  • Provides scientific views on the definition, epidemiology and etiology
    of AIDS and other retroviruses.
  • Examines market applications of Molecular Diagnostics,
    Immunodiagnostics, IT and other emerging technologies.
  • Reviews infectious disease testing analyzers marketed by Abbott,
    Beckman Coulter, bioMerieux, Ortho Clinical Diagnostics/J&J, Roche,
    Siemens, Tosoh and other suppliers.
  • Profiles over 30 leading manufacturers and potential market entrants
    developing innovative technologies and products.
  • Analyzes alternative market penetration strategies for suppliers.

Companies Mentioned

  • Abbott
  • Affymetrix
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Diamedix
  • DiaSorin
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Fujirebio
  • Grifols
  • Hologic/Gen-Probe
  • ID Biomedical/GSK
  • Kreatech/Leica
  • Lonza
  • Ortho-Clinical Diagnostics
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • SeraCare
  • Siemens
  • Takara Bio
  • Thermo Fisher/Life Technology
  • Wallac/PE
  • Wako

For more information about this report visit

Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Infectious
Disease Testing

Morinaga Milk’s New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer’s Disease

TOKYO–(BUSINESS WIRE)–Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy
product company, today announced the results of a new study
investigating the preventive effects of its new probiotic strain Bifidobacterium
A1 on a model of Alzheimer’s disease. Researchers found that B.
A1 improved spatial recognition capability, as well as
learning and memory capabilities, in cognitively deficient mice,
indicating it could play an important role in preventing the onset of
Alzheimer’s Disease in humans.1

The number of patients affected by dementia is increasing worldwide. One
report estimates there were 46.8 million people worldwide living with
dementia in 2015 and projects this number will reach 131.5 million by
2050.2 Alzheimer’s disease accounts for a large proportion of
dementia cases. Like many chronic diseases, Alzheimer’s develops slowly
for several decades before the onset of symptoms, even though
deterioration in the brain begins in the early stages. Once the disease
has developed, it is difficult to reverse it or even halt its
progression; therefore, finding effective countermeasures to prevent the
disease’s onset is a top priority for researchers.

The “gut‒brain axis,” which is the functional linkage between the brain
and gut microbiota, has attracted attention worldwide. Because
probiotics are known to have beneficial effects on gut microbiota, they
are a promising treatment for brain health. Indeed, both bifidobacteria
and lactobacillus have shown beneficial effects on anxiety and

Building on this research, Morinaga Milk investigated the ability of
probiotics to prevent the progression of Alzheimer’s disease in
collaboration with Professor Keiko Abe from The University of Tokyo and
Kanagawa Institute of Industrial Science and Technology. The study,
published in the journal Scientific Reports, revealed the
potential of B. breve A1 to prevent the onset of
Alzheimer’s disease.

Study Method

Mice were injected with amyloid β — the substance presumed to cause
Alzheimer’s disease — in order to induce cognitive dysfunction in a
model of Alzheimer’s disease. Mice in the active treatment group were
administered B. breve A1 (1 × 109 per day) orally for
10 days (B. breve A1 group). Mice in the control group were given
either saline (saline group) or a cholinesterase inhibitor, a medication
prescribed for dementia (positive control group). Cognitive function was
evaluated by a Y maze test and a passive avoidance test.

Y maze Behavioral Test Confirms Improvement of Spatial Recognition

“Spontaneous alternation” refers to the tendency of normal mice to
choose a different path when navigating a maze than the last one chosen,
indicating they remember what paths they have already tried. In this
study, amyloid β injected mice given saline showed a remarkable
reduction in spontaneous alternation rate in the Y maze test compared to
normal mice. However, the B. breve A1 group showed a significant
improvement in spontaneous alternation rate compared to the saline
group. These results indicate that B. breve A1 improves spatial
recognition capability (Fig. 1, left).

Passive Avoidance Behavioral Test Reveals Improvement in Learning
and Memory Capability

During the passive avoidance test, mice need to learn to avoid a
negative stimulus by staying away from a certain area. If they do so
successfully, it indicates they remember the negative experience.
Similar to the Y maze behavioral test, mice in the B. breve A1
group stayed longer in the area without a negative stimulus compared to
the saline group. This result indicates that B. breve A1 improves
learning and memory capabilities (Fig. 1, right).

B. breve A1 Nearly as Effective as Common Alzheimer’s Drug

The improvements in both the Y maze test and the passive avoidance test
were similar in magnitude to those observed in the positive control
group treated with a cholinesterase inhibitor, a medication commonly
prescribed for Alzheimer’s disease, indicating that B. breve A1
has similar potential to improve amyloid-induced cognitive impairment.

Hippocampus Gene Expression is Key Behind Mechanism of Action

Morinaga Milk focused on the hippocampus, the area of the brain
associated with memory and learning capabilities, by performing
comprehensive gene expression analysis in the hippocampus of the mice.
The researchers found the expression of many genes was altered;
particularly, gene groups associated with immunological reactions and
inflammation were changed, causing immunological abnormalities and
excessive inflammation in the impaired mice ingesting saline. In
contrast, the expression of the majority of these genes remained normal
in impaired mice ingesting B. breve A1 (Fig. 2).

These findings led Dr. Jin-zhong Xiao, General Manager of Morinaga
Milk’s Next Generation Science Institute, to state that “Intake of B.
A1 suppressed excessive immunological reactions and
inflammation in the brains of the mice and improved cognitive function.”
He went on to add, “Chronic inflammation of the brain is characteristic
of Alzheimer’s disease. B. breve A1’s ability to suppress
inflammation in the hippocampus is the key behind its ability to prevent
progression of the disease.” The company plans to continue to research
the effects of B. breve A1 on human subjects to further explore
its therapeutic potential for preventing Alzheimer’s disease onset.

About Morinaga Milk

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product
companies in Japan. Morinaga Milk started research on bifidobacteria in
the 1960s, inspired by the fact that bifidobacteria are the predominant
bacteria residing in the intestines of breast-fed infants. In 1969,
Morinaga Milk isolated its flagship strain Bifidobacterium longum
BB536 from an infant. Morinaga Milk excels in innovative technology and
offers various dairy products and other beneficial functional
ingredients to customers around the world.



1.   Y. Kobayashi et al. Therapeutic potential of Bifidobacterium breve
strain A1 for preventing cognitive impairment in Alzheimer’s
disease. Scientific Reports 7(1). Dec. 2017.

Alzheimer Report 2016


Morinaga Milk Industry Co., Ltd.
Mai Nozawa, +81-3-3798-0152

Truveris Appoints Sally Welborn, former head of Walmart Global Benefits to Board of Directors

Brings deep industry experience to the leading pharmaceutical data
analytics firm focused on providing everyone with greater access to
affordable medications

NEW YORK–(BUSINESS WIRE)–Truveris, Inc. today announced that Sally Welborn, the former senior
vice president of global benefits at Walmart, was elected to the
Truveris board of directors. Welborn is an innovative thought leader in
total rewards with more than 30 years of wide-ranging industry
experience and a significant national network of influential executives.

Truveris believes that everyone should have access to affordable
medication. The company combines its deep domain expertise with big data
analytics to deliver prescription drug affordability and access
solutions for plan sponsors, members and other stakeholders. The company
currently works with more than 400 pharmacy benefit plan sponsors as
well as almost 40 pharmaceutical brands.

“Sally’s deep understanding of the challenges organizations face
providing employee benefits will be a huge asset to Truveris,” said
Faisal Mushtaq, Truveris CEO. “Throughout her career, Sally has
demonstrated that she is a strategic thinker with a record of success in
implementing ground-breaking initiatives. She is a highly respected
healthcare policy expert, and we look forward to benefiting from her
experience as we work to provide greater access to affordable
medications so that everyone can live healthier lives.”

“Prescription drug affordability and accessibility is one of the most
important issues in the US today,” said Ms. Welborn. “Truveris has
unique capabilities to make a difference for payers and patients and I
am honored to join its Board.”

Prior to founding Welborn Advisory Services, Welborn was Senior Vice
President of Global Benefits at Walmart for nearly eight years. Prior to
Walmart, she was Senior Vice President of Benefits at Wells Fargo for
more than 11 years. Welborn serves as a Board Advisor for the Penn
Center for Health Incentives and Behavioral Economics. She also
currently serves on the Board of the Leapfrog Group and previously
served on the board of the National Business Group on Health, as the
Chair of the ERISA Industry Committee and as Vice Chair of the Pacific
Business Group on Health.

About Truveris

Truveris brings transparency to the prescription drug ecosystem through
data-driven innovations. Truveris’ platform offers customers – from the
individual patient to employers, retailers, pharmacy benefits
stakeholders, and manufacturers – the data and insights they need to
effectively and efficiently manage rising costs and market access
challenges. Visit to
learn more.


Truveris, Inc.
Jeff Ignaszak

Adisseo and Seventure Partners Announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and Nutrition

PARIS–(BUSINESS WIRE)–Seventure Partners, one of Europe’s leaders in financing innovation and
a world-leader in Life science microbiome investment, today announces
that it has launched AVF, the innovative venture capital fund, targeted
at supporting companies in the field of animal health, feed and
nutrition. The first close of AVF at €24m, is corner stoned by Adisseo,
an industry leader in the animal feed sector.

The livestock sector is undergoing profound changes requiring the entire
food chain to adapt accordingly and respond to strong global pressures
and changing consumer expectations. The rapidly growing world population
and the increased demand from emerging countries for animal protein
present significant challenges to the sector, as well as the requirement
to meet environmental objectives and for sustainable production within
livestock industry.

At a global level, AVF’s investment strategy focuses on two segments at
the forefront of the modern agricultural and livestock revolution: animal
health, feed and nutrition and digital technologies serving the
livestock industry.

Within the animal health sector, food digestibility, its nutritional
value and energy potential, and the traceability of the entire animal
food chain are major opportunities, as well as addressing the challenges
around limiting the environmental footprint of the industry.

In addition to the animal health and nutrition sector, the digital
agricultural technology field has seen exponential growth, partly driven
by climate change and scarcity in resources and biodiversity, as well as
heightened pressure from increasingly demanding consumers. AVF will also
finance digital innovations applied to the livestock value chain, such
as smart breeding and diagnosis, control and traceability tools.

AVF will primarily invest in innovative companies in Europe, North
America and Israel, but will also be open to strong investment proposals
from other geographies, including Asia.

Isabelle de Cremoux, CEO and Managing Partner at Seventure Partners,
stated: “Since the implementation of our new strategy in 2013, we have
launched several institutional funds with defined investment themes,
connecting prestigious strategic investors with serial entrepreneurs and
financial institutional investors. We have launched funds in Digital
technologies as well as in Life sciences. After the successful launch of Health
for Life Capital™
, which raised €160m with strategic partners such
as Danone, Novartis, Tereos, Lesaffre and Bel to invest in the
microbiome, digital innovation and in human health/nutrition/food, we
are now launching AVF, a new fund in animal health and nutrition.”

Commenting on the need for and focus of the fund, Isabelle de Cremoux
added: “This new thematic fund was created to address a very specific
and expanding need in the market: preserving animal health, gaining a
better understanding of the entire food value chain, as well as
developing technologies to cultivate and produce food in a better way.

We are proud to count Adisseo among the privileged partners who share
our vision and we will announce our first investments in the near

Jean-Marc Dublanc, CEO of Adisseo, stated: “Adisseo is a unique company
committed to strategic investments in new disruptive technologies, in
order to enrich our portfolio of R&D innovations while respecting a mode
of sustainable growth. Our ambition is to become one of the leaders in
Feed Ingredient Specialties and the experienced partner of choice in
animal nutrition.

For this reason, we have been investing significantly for many years in
our research programs and industrial development projects.

With AVF, our goal is to invest in strategic collaborations combining
the agility of start-ups with Adisseo’s expertise. As such, Seventure
was a natural partner of choice and we are pleased to become a strategic
investor in AVF.”


Notes to Editors

About Seventure Partners

With over €690m in assets under management as of the end of 2017,
Seventure Partners is a leading venture capital firm in Europe. Since
1997, Seventure Partners has been investing in innovative businesses
with high growth potential in two fields: Digital technologies in France
and Germany, and Life sciences across Europe, Israel and North America.

In Life sciences, the four areas of focus include biotechnology and
pharmaceuticals, digital/connected health and medtech, industrial
biotechnology, and last but not least: the MICROBIOME, nutrition,
foodtech and personalized medicine. Investments can range between €500k
and €10m per round, or up to €20m per company, from early to late stage.

In December 2013, Seventure Partners successfully launched Health for
Life Capital
™ that invests in lifesciences worldwide, with a core
focus on the microbiome revolution and its applications in human health
and nutrition. The €160m fund has attracted strategic investments from
prestigious organizations including Danone, Tereos, Tornier, Lesaffre,
Bel and Novartis, as well as entrepreneurs and financial institutions.

In March 2018, Seventure Partners launched AVF, a new fund dedicated to
invest in innovative solutions for animal nutrition, feed and health.
Adisseo is one of the first strategic partners of the fund.

For more details:
Twitter: @seventurep

About Adisseo

Adisseo is one of the world’s leading experts in feed additives. The
group relies on its seven research centers and its production sites
based in Europe and China to design, produce and market nutritional
solutions for sustainable animal feed.

With more than 1,900 employees, it serves around 2,600 customers in over
100 different countries through its global distribution network.

Adisseo is listed on the Shanghai Stock Exchange and is one of the main
subsidiaries of China National BlueStar, leader in the Chinese chemical
industry with nearly 25,000 employees and a turnover of 6.4 billion

Adisseo Corporate website:

About Adisseo products and services

Adisseo offers its customers 4 forms of an essential amino acid,
methionine for poultry and swine (Rhodimet® AT88 and Rhodimet® NP99) and
protected methionine for ruminants (Smartamine® M and MetaSmart®), a
complete range of vitamins (Microvit®), multi-activities enzymes
(Rovabio®), and specialty Selisseo® and Alterion®.

Adisseo supports the development of its customers by providing valuable
and innovative services such as PNE – Precise Nutrition Evaluation.

Adisseo Brands website:


Seventure Partners
At the Company
Isabelle de Cremoux
and Managing Partner of Seventure Partners
Tel: + 33 1 58 19 22 77

Agence Yucatan
Caroline Prince-Albagnac
+33 1 53 63 27 35
Sue Charles/ Gemma Harris
Tel: +44 20 7866 7860
Media contacts:

In China
First Avenue
Grace Xu
+ 86 13651838486

Fabienne Lissak
Tel: +33 140 22 66 45
/ +33 6 86 58 06 90

2018 Global Markets for Vaccine Technologies: Industry Environment, Strategies, Market Influences, and Driving Forces –

Markets for Vaccine Technologies”
report has been added to’s

The report intends to explain the critical trends in the vaccine
industry. It discusses the market determinants, which act as motivating
or restraining factors, and provides insights to the stakeholders and
potential entrants.

This study contributes to the areas of market growth among vaccine
manufacturers and end users. The report provides useful information to
all the market players, potential entrants, government agencies and
other interested parties.

Key Highlights

  • Analyses of global market trends, with data from 2016 and 2017, and
    projections of compound annual growth rates (CAGRs) through 2022
  • A review of vaccine technology and its challenges, innovations,
    opportunities, and regulatory hurdles
  • Evaluations of market sizes and developments for vaccine classes
    (prophylactic and therapeutic), vaccine types (inactivated, conjugate,
    attenuated, recombinant vector, subunit, toxoid, combination, and
    dendritic cells), vaccine end users (humans and animals) and disease
    indications (infectious, cancer, and allergy)
  • Examination of the industry environment, strategies, market
    influences, and driving forces
  • Identification of regional market sizes, prices, and trends
  • Analysis of relevant patents
  • Company profiles of major key players in the market, including Abbott
    Laboratories., Baxter International Inc., Bayer Animal Health, GE
    Healthcare, Glaxosmithkline Plc, Johnson & Johnson, LG Life Sciences.,
    Novartis Pharma Ag and Thermo Fisher Scientific

Key Topics Covered

1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Analyst’s Credentials

2 Summary and Highlights

3 Market and Technology Background

  • Definitions
  • Immune System and Vaccines
  • How Vaccines Work
  • Types of Immunity
  • Advantages of Vaccination
  • History of Vaccines
  • Types of Vaccines
  • Adjuvants and Excipients
  • Infectious Diseases Preventable by Vaccines
  • Rapid Manufacturing for Pandemics
  • Laws and Regulations
  • Opportunities
  • Current Situation

4 Market Breakdown by Human Vaccine

  • Types of Human Vaccines
  • Attenuated (Live) Vaccines
  • Inactivated Vaccines
  • Conjugate Vaccines
  • rDNA/DNA Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Other/Combination Vaccines
  • Vaccine by Age Group
  • Vaccine by Disease Type

5 Market Breakdown by Animal Vaccines

  • Animal Vaccines
  • Market by Type

6 Patent Analysis

  • Patents by Year
  • Patents by Vaccine Type
  • Patents by Patent Office
  • Patents by Company
  • Patents by Assignee

7 Market Breakdown by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of APAC
  • Rest of World

8 Companies Profiled

  • Abbott Laboratories
  • Aeras Global
  • Astellas Pharma Inc.
  • Astrazeneca Plc
  • Baxter International Inc.
  • Bayer Animal Health
  • Bharat Biotech International Ltd.
  • Bio-Manguinhos
  • Biological E. Ltd.
  • Bioproperties Pty Ltd.
  • Boehringer Ingelheim Gmbh
  • CSL Ltd.
  • Elanco Animal Health
  • Emergent Biosolutions Inc.
  • Fatro Spa
  • GE Healthcare
  • Glaxosmithkline Plc
  • Johnson & Johnson Inc.
  • LG Life Sciences
  • Maxcyte Inc.
  • Merck & Co. Inc.
  • Merial Sas
  • Novartis Pharma Ag
  • Panacea Biotec Ltd.
  • Pfenex Inc.
  • Pfizer Inc.
  • Profectus Biosciences Inc.
  • PT Bio Farma
  • Replikins Ltd.
  • Sanofi Pasteur
  • Serum Institute Of India Ltd.
  • Statens Serum Institut
  • Thermo Fisher Scientific
  • Xeme Biopharma Inc.
  • Zoetis Inc.

For more information about this report visit

Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Vaccines

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

First FDA-Approved Regimen in Frontline Stage III or IV Classical
Hodgkin Lymphoma in More Than 40 Years

FDA Approval Based on Clinical Trial Results from the Phase 3
ECHELON-1 Clinical Trial

Label Expansion Represents Fifth Indication for ADCETRIS in the U.S.;
ECHELON-1 Trial Also Converts Prior Accelerated Approval to Regular
Approval in Treatment of Relapsed Systemic Anaplastic Large Cell Lymphoma

Genetics, Inc.
(Nasdaq: SGEN) announced today that the U.S. Food and
Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) in
combination with chemotherapy in adult patients with previously
untreated Stage III or IV classical Hodgkin lymphoma. The approval is
based on the successful outcome of the phase 3 ECHELON-1 clinical trial
that compared ADCETRIS plus AVD (Adriamycin, vinblastine and
dacarbazine) to ABVD (Adriamycin, bleomycin, vinblastine and
dacarbazine). In addition, data from the ECHELON-1 trial converted the
U.S. accelerated approval of ADCETRIS for the treatment of adults with
systemic anaplastic large cell lymphoma (sALCL) after failure of at
least one multi-agent chemotherapy regimen to regular approval. In
October 2017, the FDA granted Breakthrough Therapy Designation (BTD) to
ADCETRIS in combination with chemotherapy for the frontline treatment of
patients with advanced classical Hodgkin lymphoma. The FDA also granted
Priority Review for the supplemental Biologics License Application
(BLA), and the Prescription Drug User Fee Act (PDUFA) target action date
was May 1, 2018.

“The standard of care for treating newly diagnosed advanced Hodgkin
lymphoma has not changed in more than four decades. For years, the
physician community has been conducting clinical trials to identify
improved regimens that are both less toxic and more effective to no
avail,” said Joseph M. Connors, M.D., FRCPC, Clinical Director, Center
for Lymphoid Cancer at BC Cancer in Vancouver, Canada. “The ECHELON-1
study results demonstrated superior efficacy of the ADCETRIS plus
chemotherapy regimen when compared to the standard of care while
removing bleomycin, an agent that can cause unpredictable and sometimes
fatal lung toxicity, completely from the regimen. This represents a
meaningful advance for this often younger patient population.”

This is the fifth FDA-approved indication for ADCETRIS, which also has
regular approval for adult patients with: (1) classical Hodgkin lymphoma
(cHL) at high risk of relapse or progression as post-autologous
hematopoietic stem cell transplantation (auto-HSCT) consolidation, (2)
cHL after failure of auto-HSCT or failure of at least two prior
multi-agent chemotherapy regimens in patients who are not auto-HSCT
candidates, (3) sALCL after failure of at least one prior multi-agent
chemotherapy regimen, and (4) primary cutaneous anaplastic large cell
lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have
received prior systemic therapy.

“Currently, up to 30 percent of newly diagnosed advanced-stage classical
Hodgkin lymphoma patients will experience disease progression after
treatment with the current standard of care, representing a significant
need for improved treatment options for these often younger patients,”
said Clay Siegall, Ph.D., President and Chief Executive Officer of
Seattle Genetics. “The ECHELON-1 trial was a bold, five-year effort to
redefine the frontline treatment of Stage III/IV classical Hodgkin
lymphoma and provide patients with a more effective treatment regimen.
In the ECHELON-1 study, ADCETRIS plus AVD was shown to have superior
efficacy to ABVD. With today’s FDA approval, the physician and patient
community have a new treatment option for previously untreated Stage III
or IV Hodgkin lymphoma patients. We want to thank all of the patients,
physicians and their staff who participated in the ECHELON-1 trial which
supported the FDA approval of this novel regimen.”

The FDA approval is based on positive results from a phase 3 trial
called ECHELON-1 that were presented at the 59th American
Society of Hematology (ASH) annual meeting in December 2017 with
simultaneous publication in the New England Journal of Medicine.
Results from the ECHELON-1 trial in 1,334 Stage III or IV classical
Hodgkin lymphoma patients included:

  • The trial achieved its primary endpoint with the combination of
    ADCETRIS plus AVD resulting in a statistically significant improvement
    in modified progression-free survival (PFS) versus the control arm of
    ABVD as assessed by an Independent Review Facility (IRF) (HR 0.77; 95%
    CI, 0.60-0.98; p-value=0.035). This corresponds to a 23 percent
    reduction in the risk of progression, death or need for additional
    anticancer therapy in patients not in complete response (CR) after
    frontline treatment.
  • Overall survival (OS) was a key secondary endpoint and the rate of CR
    per IRF assessment at the end of the randomized regimen was a
    secondary endpoint. At the time of the modified PFS analysis, an
    interim OS analysis trended in favor or the ADCETRIS plus AVD arm, but
    did not demonstrate significant difference (HR 0.72; 95% CI,
    0.44-1.17; p-value=0.19). The CR rate was 73 percent on the ADCETRIS
    plus AVD arm and 70 percent on the ABVD arm.
  • The safety profile of ADCETRIS plus AVD in the ECHELON-1 trial was
    generally consistent with that known for the single-agent components
    of the regimen.
  • The most common adverse events of any grade that occurred in at least
    10 percent of patients in the ADCETRIS plus AVD arm were: anemia,
    neutropenia, peripheral sensory neuropathy, constipation, vomiting,
    diarrhea, pyrexia, decreased weight, stomatitis, abdominal pain,
    febrile neutropenia, bone pain, insomnia, decreased appetite, back
    pain, rashes/eruptions/exanthemas, dyspnea, peripheral motor
    neuropathy, and increased alanine aminotransferase. In both the
    ADCETRIS plus AVD and ABVD arms, the most common Grade 3 or 4 events
    were neutropenia, febrile neutropenia, and anemia.
  • Based on ECHELON-1 clinical trial results, prophylactic growth factors
    (G-CSF) should be administered starting at cycle one for Stage III or
    IV classical Hodgkin lymphoma patients receiving ADCETRIS plus AVD.

About Classical Hodgkin Lymphoma

Lymphoma is a general term for a group of cancers that originate in the
lymphatic system. There are two major categories of lymphoma: Hodgkin
lymphoma and non-Hodgkin lymphoma. Classical Hodgkin lymphoma is
distinguished from other types of lymphoma by the presence of one
characteristic type of cell, known as the Reed-Sternberg cell. The
Reed-Sternberg cell expresses CD30.

According to the American Cancer Society, approximately 8,500 cases of
Hodgkin lymphoma will be diagnosed in the United States during 2018 and
more than 1,000 will die from the disease. Approximately half of all
newly diagnosed Hodgkin lymphoma patients have Stage III/IV disease.
According to the Lymphoma Coalition, over 62,000 people worldwide are
diagnosed with Hodgkin lymphoma each year and approximately 25,000
people die each year from this cancer.


ADCETRIS is being evaluated broadly in more than 70 clinical trials,
including two ongoing phase 3 studies: the ECHELON-2 trial in frontline
mature T-cell lymphomas and the CHECKMATE 812 trial of ADCETRIS in
combination with Opdivo (nivolumab) for relapsed/refractory Hodgkin

ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached
by a protease-cleavable linker to a microtubule disrupting agent,
monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary
technology. The ADC employs a linker system that is designed to be
stable in the bloodstream but to release MMAE upon internalization into
CD30-expressing tumor cells.

ADCETRIS injection for intravenous infusion has received FDA regular
approval for five indications in adult patients with: (1) previously
untreated Stage III or IV classical Hodgkin lymphoma (cHL), in
combination with chemotherapy, (2) cHL at high risk of relapse or
progression as post-autologous hematopoietic stem cell transplantation
(auto-HSCT) consolidation, (3) cHL after failure of auto-HSCT or failure
of at least two prior multi-agent chemotherapy regimens in patients who
are not auto-HSCT candidates, (4) sALCL after failure of at least one
prior multi-agent chemotherapy regimen, and (5) primary cutaneous
anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis
fungoides (MF) who have received prior systemic therapy.

Health Canada granted ADCETRIS approval with conditions for relapsed or
refractory Hodgkin lymphoma and sALCL in 2013, and non-conditional
approval for post-autologous stem cell transplantation (ASCT)
consolidation treatment of Hodgkin lymphoma patients at increased risk
of relapse or progression.

ADCETRIS received conditional marketing authorization from the European
Commission in October 2012. The approved indications in Europe are: (1)
for the treatment of adult patients with relapsed or refractory
CD30-positive Hodgkin lymphoma following ASCT, or following at least two
prior therapies when ASCT or multi-agent chemotherapy is not a treatment
option, (2) the treatment of adult patients with relapsed or refractory
sALCL, (3) for the treatment of adult patients with CD30-positive
Hodgkin lymphoma at increased risk of relapse or progression following
ASCT, and (4) for the treatment of adult patients with CD30-positive
cutaneous T-cell lymphoma (CTCL) after at least one prior systemic

ADCETRIS has received marketing authorization by regulatory authorities
in 71 countries for relapsed or refractory Hodgkin lymphoma and sALCL.
See select important safety information, including Boxed Warning, below.

Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the
terms of the collaboration agreement, Seattle Genetics has U.S. and
Canadian commercialization rights and Takeda has rights to commercialize
ADCETRIS in the rest of the world. Seattle Genetics and Takeda are
funding joint development costs for ADCETRIS on a 50:50 basis, except in
Japan where Takeda is solely responsible for development costs.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company dedicated to
improving the lives of people with cancer through targeted therapies.
The company’s industry-leading antibody-drug conjugate (ADC) technology
harnesses the targeting ability of antibodies to deliver cell-killing
agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS®
(brentuximab vedotin) for the treatment of several types of
CD30-expressing lymphomas. The company is also advancing a robust
pipeline of novel therapies for solid tumors and blood-related cancers
designed to address significant unmet medical needs and improve
treatment outcomes for patients. More information can be found at
and follow @SeattleGenetics on Twitter.

ADCETRIS (brentuximab vedotin) U.S. Select Important Safety


JC virus infection resulting in PML and death can occur in
ADCETRIS-treated patients.


ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g.,
interstitial infiltration and/or inflammation).

Warnings and Precautions

  • Peripheral neuropathy (PN): ADCETRIS causes PN that is
    predominantly sensory. Cases of motor PN have also been reported.
    ADCETRIS-induced PN is cumulative. Monitor for symptoms such as
    hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning
    sensation, neuropathic pain, or weakness. Institute dose modifications
  • Anaphylaxis and infusion reactions: Infusion-related reactions
    (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor
    patients during infusion. If an IRR occurs, interrupt the infusion and
    institute appropriate medical management. If anaphylaxis occurs,
    immediately and permanently discontinue the infusion and administer
    appropriate medical therapy. Premedicate patients with a prior IRR
    before subsequent infusions. Premedication may include acetaminophen,
    an antihistamine, and a corticosteroid.
  • Hematologic toxicities: Fatal and serious cases of febrile
    neutropenia have been reported with ADCETRIS. Prolonged (≥1 week)
    severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can
    occur with ADCETRIS. Administer G-CSF primary prophylaxis starting
    with Cycle 1 for previously untreated patients who receive ADCETRIS in
    combination with chemotherapy for Stage III or IV HL. Monitor complete
    blood counts prior to each ADCETRIS dose. Consider more frequent
    monitoring for patients with Grade 3 or 4 neutropenia. Monitor
    patients for fever. If Grade 3 or 4 neutropenia develops, consider
    dose delays, reductions, discontinuation, or G-CSF prophylaxis with
    subsequent doses.
  • Serious infections and opportunistic infections: Infections
    such as pneumonia, bacteremia, and sepsis or septic shock (including
    fatal outcomes) have been reported in ADCETRIS-treated patients.
    Closely monitor patients during treatment for bacterial, fungal, or
    viral infections.
  • Tumor lysis syndrome: Closely monitor patients with rapidly
    proliferating tumor and high tumor burden.
  • Increased toxicity in the presence of severe renal impairment: The
    frequency of ≥Grade 3 adverse reactions and deaths was greater in
    patients with severe renal impairment compared to patients with normal
    renal function. Avoid use in patients with severe renal impairment.
  • Increased toxicity in the presence of moderate or severe hepatic
    The frequency of ≥Grade 3 adverse reactions and deaths
    was greater in patients with moderate or severe hepatic impairment
    compared to patients with normal hepatic function. Avoid use in
    patients with moderate or severe hepatic impairment.
  • Hepatotoxicity: Fatal and serious cases have occurred in
    ADCETRIS-treated patients. Cases were consistent with hepatocellular
    injury, including elevations of transaminases and/or bilirubin, and
    occurred after the first ADCETRIS dose or rechallenge. Preexisting
    liver disease, elevated baseline liver enzymes, and concomitant
    medications may increase the risk. Monitor liver enzymes and
    bilirubin. Patients with new, worsening, or recurrent hepatotoxicity
    may require a delay, change in dose, or discontinuation of ADCETRIS.
  • PML: Fatal cases of JC virus infection resulting in PML and
    death have been reported in ADCETRIS-treated patients. First onset of
    symptoms occurred at various times from initiation of ADCETRIS
    therapy, with some cases occurring within 3 months of initial
    exposure. Other possible contributory factors other than ADCETRIS
    include prior therapies and underlying disease that may cause
    immunosuppression. Consider PML diagnosis in patients with new-onset
    signs and symptoms of central nervous system abnormalities. Hold
    ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is
  • Pulmonary toxicity: Fatal and serious events of noninfectious
    pulmonary toxicity including pneumonitis, interstitial lung disease,
    and acute respiratory distress syndrome have been reported. Monitor
    patients for signs and symptoms, including cough and dyspnea. In the
    event of new or worsening pulmonary symptoms, hold ADCETRIS dosing
    during evaluation and until symptomatic improvement.
  • Serious dermatologic reactions: Fatal and serious cases of
    Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
    have been reported with ADCETRIS. If SJS or TEN occurs, discontinue
    ADCETRIS and administer appropriate medical therapy.
  • Gastrointestinal (GI) complications: Fatal and serious cases of
    acute pancreatitis have been reported. Other fatal and serious GI
    complications include perforation, hemorrhage, erosion, ulcer,
    intestinal obstruction, enterocolitis, neutropenic colitis, and ileus.
    Lymphoma with preexisting GI involvement may increase the risk of
    perforation. In the event of new or worsening GI symptoms, perform a
    prompt diagnostic evaluation and treat appropriately.
  • Embryo-fetal toxicity: Based on the mechanism of action and
    animal studies, ADCETRIS can cause fetal harm. Advise females of
    reproductive potential of the potential risk to the fetus, and to
    avoid pregnancy during ADCETRIS treatment and for at least 6 months
    after the final dose of ADCETRIS.

Most Common (≥20%) Adverse Reactions: neutropenia, anemia, peripheral
sensory neuropathy, nausea, fatigue, constipation, diarrhea, vomiting,
and pyrexia.

Drug Interactions

Concomitant use of strong CYP3A4 inhibitors or inducers, or P-gp
inhibitors, has the potential to affect the exposure to monomethyl
auristatin E (MMAE).

Use in Specific Populations

Moderate or severe hepatic impairment or severe renal impairment: MMAE
exposure and adverse reactions are increased. Avoid use.

Advise males with female sexual partners of reproductive potential to
use effective contraception during ADCETRIS treatment and for at least 6
months after the final dose of ADCETRIS.

Advise patients to report pregnancy immediately and avoid breastfeeding
while receiving ADCETRIS.

For additional Important Safety Information, including BOXED WARNING,
please see the full Prescribing Information for ADCETRIS at

Forward-Looking Statements

Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the potential
utilization of ADCETRIS (brentuximab vedotin) for patients with
previously untreated Stage III or IV classical Hodgkin lymphoma. Actual
results or developments may differ materially from those projected or
implied in these forward-looking statements due to factors such as
utilization and adoption of the approved treatment regimen by
prescribing physicians, competitive conditions including the
availability of alternative treatment regimens, the availability and
extent of reimbursement, the risk of adverse events, and adverse
regulatory action. More information about the risks and uncertainties
faced by Seattle Genetics is contained under the caption “Risk Factors”
included in the company’s Annual Report on Form 10-K for the year ended
December 31, 2017 filed with the Securities and Exchange
Commission. Seattle Genetics disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.


Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
Larson, 425-527-4180

USDA Biobased Economy Report Indicates Potential for Rural Prosperity with Renewable Chemicals

WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) today applauded USDA’s
release of a new report, “Indicators of the U.S. Biobased Economy.”

The report measures substantial economic growth, job creation, and
household income for the agricultural sector from biofuel and bioenergy
production. Moreover, it indicates great potential for additional
prosperity from future growth in renewable chemicals and biobased

Brent Erickson, executive vice president of BIO’s Industrial &
Environmental Section, said, “The biobased economy is approaching a
tipping point in its growth and maturation. The economic impact is

calculates that the global economic value of the biobased economy

including industrial biotechnology, renewable chemicals and polymers,
biofuels, enzymes and biobased materials – is $355.28 billion. Looking
at the new USDA Indicators report and other sources, we estimate that
the United States generates 58 percent of the global value of biobased
manufacturing, or more than $205 billion. And that economic activity
supports employment for 1.66 million U.S. workers.

“The growth of the biobased economy has been supported by good federal
policy that strengthens the agricultural sector and rural America. For
instance, Farm Bill energy title programs have compiled a record of
success that deserves to be continued. We look forward to working with
USDA and Congress to build on that success and reauthorize the programs.”

About BIO

BIO is the world’s largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention
, the world’s largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW
is BIO’s blog chronicling “innovations transforming our world” and the
BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe
to the BIO Newsletter

Upcoming BIO Events


International Convention

World Congress on Industrial Biotechnology

June 4-7, 2018 July 16-19, 2018
Boston, MA Philadelphia, PA


Biotechnology Innovation Organization (BIO)
Paul Winters,

Ortho RI Surgeon Leading the Way in Opioid Epidemic Initiative

Opioid Sparing Pathway promotes non-narcotic approach to pain
management at South County Health Orthopedics Center

PROVIDENCE, R.I.–(BUSINESS WIRE)–#OpioidEpidemicDrs. Henry Cabrera and Michael Bradley ease pain without opioid

There are very few societal issues that have caught widespread attention
more than the opioid crisis. For years, opioid-based drugs have been
administered to patients during and after surgery for their
effectiveness in eliminating pain. But the negative effects of these
drugs, pharmaceutical derivatives of heroine, can range from nausea to
dependency. In an effort to combat the opioid crisis, two members of the
South County Health medical staff, anesthesiologist, Henry Cabrera, MD,
and orthopedic surgeon, Michael Bradley, MD, have acknowledged the
problem and are doing something about it, without sacrificing patients’
outcomes or experience.

“The pendulum has swung,” Dr. Bradley said. “We’re not loading people up
with narcotics to eliminate pain. We’re having them understand that you
will have some pain and we’ll help you get through it.”

Drs. Cabrera and Bradley recently collaborated on an opioid sparing
pathway to minimize, or in some cases eliminate, opioid use for
orthopedic surgical patients.

“Our goal is to get patients out of the hospital sooner and healthier,
without the negative side effects of these drugs,” Dr. Cabrera said.
“For years we were trained to use narcotics to get patients’ pain scores
down to zero. Anything above a four was unacceptable. To follow the
opioid sparing pathway as it is intended, medical staff and patients
need to recognize and accept that there will be some pain. It’s a
complete cultural change.”

The physicians describe opioid sparing as a four-part pathway, “a
multi-modal attack on pain.” Green Line Apothecary, a local, independent
pharmacy in Wakefield is participating in the initiative.

Three days prior to surgery, patients can go to Green Line Apothecary to
obtain a blister pack of pre-ordered medication. Each pack contains an
analgesic such as Tylenol, an anti-inflammatory medication, gabapentin
(a neuropathic pain pill), and a narcotic. The pack also contains a
blood clotting medication, unrelated to pain.

“We never used to start treating before the surgery happens. Part of the
theory behind this is that we reduce any inflammatory processes that
occur by treating it before it actually happens,” Dr. Cabrera said.

The intra-operative section, which effects patients during surgery, has
been addressed with the use of a spinal anesthetic as opposed to a
general anesthetic.

“We do nerve blocks whenever possible. That decreases the amount of
narcotics patients would need afterwards,” Dr. Cabrera said.

The post-operative part of the pathway addresses the types of drugs
given between the time a patient is discharged from the recovery room
and then discharged from the hospital. When appropriate for the patient,
pain is controlled mainly with non-narcotic options. This helps to
reduce nausea, constipation, and other adverse side effects of
pain-killing narcotics that delay recovery.

The physicians recently added a fourth part, post-discharge, to address
a patient’s comfort from the last day in the hospital to about a week

A new mindset
From the patients’ perspectives, anesthesia
and pain are the most concerning aspects of surgery. From a patient care
perspective, the pain scale is considered to be the fifth vital sign,
after body temperature, pulse rate, respiration rate, and blood
pressure. Whenever a patient indicates that he or she is in pain, common
practice is to administer a narcotic for relief.

At South County Health, this process change has already begun with
re-education and a new mindset for physicians, nurses, and patients, Dr.
Cabrera said. Representatives from nursing, pharmacy, performance
improvement, physical therapy, and home health – key services for the
orthopedics center – meet regularly to ensure that the pathway is
effectively used.

The cultural change also extends to physical therapy. In the past,
patients would take a pain-relieving narcotic prior to their therapy.
Using the pathway, non-narcotic analgesics are taken pre- and
post-therapy so that the patient can better tolerate the discomfort of
physical strain. The goal, however, is always to balance patient comfort
with positive outcomes.

“If the level of pain begins to compromise patient success, we’ll
reassess the pathway used for that patient and change as necessary,” Dr.
Bradley said.

The pathway was rolled out in December 2017. The South County Health
Orthopedics Center was used to introduce the initiative, given the
volume of patients who receive hip and knee surgeries at South County
Hospital. To date, approximately 200 patients have benefitted from the
method. Some of the orthopedic patients who have undergone recent
surgery using the opioid sparing pathway, were given narcotics for pain
during previous surgeries.

“Anecdotally, a couple of people have called with concerns about how
much pain they are in, but it looks like our pain scores are not going
up, and people are getting out of the hospital quicker,” Dr. Bradley

Building on the pathway’s success
While the pathway was
originally intended for use in orthopedic patients, Dr. Cabrera adapted
the pathway to be used in other surgical specialties. It is believed
that no other hospitals in New England have addressed the opioid crisis
and narcotic use to this scale.

“There was no model for administering non-opioid options for pain relief
with surgical patients. We had to create our own,” Dr. Cabrera said.

“This is really changing the way we look at perioperative pain. I
haven’t seen it to this scale. It’s no longer ‘what’s your pain, here’s
your pill’ mindset, but ‘how can we help you’. Ice, relaxation
techniques, Reiki – whatever works, we try it,” Dr. Bradley said.

The opioid sparing pathway is designed to be the default in
post-operative pain management, understanding that narcotics will
continue to play a role in patient care when necessary.

In March or April, the first quarter results of admitted patients will
be available. Discharged patients who are rehabilitating at home are
surveyed at intervals of six weeks, three months, and six months. Those
results will also be factored into the measure of success.

“It’s successful already because it’s changing the way people think, and
it’s addressing and acknowledging the opioid crisis,” Dr. Bradley said.

About Ortho RI

Ortho RI is regarded as a top practice offering comprehensive
musculoskeletal care, with seven hospital affiliations, 11 convenient
locations, and more than 100 orthopedic specialists, therapists and
trainers. The medical group’s areas of expertise include: hand, joint,
pain management, shoulder, spine, sports medicine, joint reconstruction,
primary care sports medicine, podiatry and robotic joint replacement.
Ortho RI also offers physical and occupational therapy, athletic
training, advanced imaging, and durable medical equipment.


Ortho RI
Michele Inkley, 401-519-3675

MellingMedical Awarded Federal Supply Contract for Pharmaceuticals

Expanding Business to Enhance Access and Care to Pharmaceutical

ALEXANDRIA, Va.–(BUSINESS WIRE)–#Healthcare–MellingMedical, a licensed pharmaceutical wholesale distributor and
verified Service Disabled Veteran Owned Small Business (SDVOSB), was
recently awarded a Federal Supply Schedule 65IB Drugs, Pharmaceuticals
and Hematology Related Products (Contract Number 36F79718D0378). This
contract provides 72 pharmaceutical products needed to improve care at
Veterans Administration (VA) Medical Centers, VA Consolidated Mail
Outpatient Pharmacies (CMOPs), Defense (DoD) Medical Centers and other
government health agencies.

“We are honored to provide better access to cost-effective
pharmaceutical products to the Department of Veterans Affairs serving
our Veterans,” said Christopher Melling, CEO and founder, a Desert Storm
Navy veteran. “As a veteran-owned small business, we’re committed to
improving the care available to those who serve our country.”

MellingMedical holds a Medical Equipment and Surgical Supply Schedule
(Med/Surg), as well as a Pharmaceutical Schedule, and currently serves
more than 160 VA Medical Centers, all seven VA CMOPs, 95 DoD Medical
Facilities and Health and Human Services (HHS), including Indian Health
Services (IHS) and the Center for Disease Control (CDC). MellingMedical
provides access to innovative and cost-effective healthcare solutions in
ophthalmology, optometry, wound care and diabetes management, urology
and post-traumatic stress, in addition to a full range of pharmaceutical
products through partnership with more than 50 recognized quality
manufacturing partners.

To learn more, visit
or contact the company at


For MellingMedical
Trina Barlow

To Accelerate Research on Anti-aging and Age-related Disease, In Light of the Near Future of a Super-aging Society, Notice of Transfer of Hakushindo Pharmaceutical Co., Ltd. Shares

TOKYO–(BUSINESS WIRE)–Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo,
CEO Daizo Shimamura) provided research funding to the Project Research
Center For Clinical Trials and Preventative Medicine at the Hiroshima
University Graduate School of Biomedical & Health Sciences to carry out
the world’s first clinical study regarding long-term (24 weeks) oral
intake of NMN (β-nicotinamide mononucleotide). The name of the trial is:
Evaluation of the effects of long-term ingestion of nicotinamide
mononucleotide (NMN). The purpose of the trial is to confirm an increase
in rejuvenating hormones, activation of mitochondria, and to confirm the
emergence of sirtuin genes 1 and 2.
Hakushindo Pharmaceutical has
recently transferred all of its shares to Shinkowa Pharmaceutical Co.,
Ltd. (head office: Chuo-ku, Tokyo, CEO, Megumi Tanaka).

The clinical trial on oral NMN intake is currently underway at the
Hiroshima University Graduate School of Biomedical & Health Sciences:
Project Research Center For Clinical Trials and Preventative Medicine.
trial ID: UMIN000025739

The NMN source used in the clinical trial at the Hiroshima University
Graduate School of Biomedical & Health Sciences: Project Research Center
For Clinical Trials and Preventative Medicine was purchased from
Shinkowa Pharmaceutical Co., Ltd., and the completion of Hakushindo
Pharmaceutical’s defined role in this clinical trial is the reason for
the transfer of the company’s shares to Shinkowa Pharmaceutical Co., Ltd.

In the future, Hakushindo Pharmaceutical intends to actively carry out
new clinical studies of NMN, as well as other related clinical studies.

Company profile
Company name: Hakushindo Pharmaceutical Co., Ltd.
Daizo Shimamura
Location: Shinjuku-ku, Tokyo
description: Health food and cosmetics sales business, clinical research


For inquiries related to this matter
Hakushindo Pharmaceutical Co.,
Daizo Shimamura, +81-3-5322-2868
Fax: +81-3-5322-2869
Please make all inquiries by email.